Chiron Corp., of Emeryville, Calif., said Chiron Vaccines President John Lambert was selected to serve on the board of the Global Alliance for Vaccines and Immunization.

Corautus Genetics Inc., of Atlanta, elected Robert Atwood to its board.

Cytokine PharmaSciences Inc., of King of Prussia, Pa., elected David Robinson to its board.

Dendreon Corp., of Seattle, promoted Robert Hershberg to senior vice president and chief medical officer.

Exelixis Inc., of South San Francisco, appointed Frank Karbe senior vice president and chief financial officer.

Favrille Inc., of San Diego, added Peter Hutt to its board.

Galen Capital Group LLC, of McLean, Va., added Ronald Pion as special adviser.

Genaera Corp., of Plymouth Meeting, Pa., elected Osagie Imasogie to its board.

Igeneon AG, of Vienna, Austria, added Manfred Rudiger as chief operating officer.

International AIDS Vaccine Initiative in New York added Emilio Emini as senior vice president and chief of vaccine development.

Inyx Inc., of New York, added John Hammer as vice president, development of its subsidiary Inyx Pharma Ltd.

Memory Pharmaceuticals Corp., of Montvale, N.J., appointed Dennis Keane chief financial officer.

MGI Pharma Inc., of Minneapolis, elected Waneta Tuttle and Gilla Kaplan to its board.

Microbia Inc., of Cambridge, Mass., added Christopher Walsh to its board.

NaPro BioTherapeuticcs Inc., of Boulder, Colo., added Paul Bunn, Theodore Friedmann, Susan Gross and Stephen Morse to its scientific advisory board.

Novavax Inc., of Columbia, Md., appointed Gale Smith vice president, vaccine development and Raymond Hage vice president, marketing.

Pharsight Corp., of Mountain View, Calif., named John McCarthy senior scientist and clinical consultant for its strategic consulting group.

Qiagen NV, of Venlo, the Netherlands, added Noel Doheny as vice president solutions for molecular diagnostics. He also will be part of the executive committee.

Rib-X Pharmaceuticals Inc., of New Haven, Conn., appointed Venki Ramakrishnan to its scientific advisory board.

Transkaryotic Therapies Inc., of Cambridge, Mass., added Paul Martha as vice president, clinical affairs.

No Comments